Content area

|
|

Fæno- eller genotypetest for dihydropyrimidindehydrogenase-mangel før fluoropyrimidinbehandling

Forfatter(e)

Stig Ejdrup Andersen1, Niels Herluf Paulsen2, Per Pfeiffer3, Camilla Qvortrup4 & Per Damkier2, 5

1) Klinisk Farmakologisk Enhed, Sjællands Universitetshospital, Roskilde, 2) Afdeling for Klinisk Biokemi og Farmakologi, Odense Universitetshospital, 3) Onkologisk Afdeling, Odense Universitetshospital, 4) Onkologisk Afdeling, Rigshospitalet, 5) Klinisk Institut, Det Sundhedsvidenskabelige Fakultet, Syddansk Universitet

Ugeskr Læger 2021;183:V07200556

Reference: 
Ugeskr Læger 2021;183:V07200556
Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine

Stig Ejdrup Andersen, Niels Herluf Paulsen, Per Pfeiffer, Camilla Qvortrup & Per Damkier

Ugeskr Læger 2021;183:V07200556

Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Christen Ravn | 13/06
4 kommentarer
af Rasmus Philip Nielsen | 13/06
2 kommentarer
af Carsten Reidies Bjarkam | 10/06
1 Kommentar
af Inger Ros | 08/06
4 kommentarer
af Birger Kreutzfeldt | 08/06
1 Kommentar
af Leo Kirkegaard Winther | 07/06
1 Kommentar
af Andreas Sven Lennart Saine Granlund | 07/06
1 Kommentar